CJC-1295 and Ipamorelin Research: Dual GH Axis Receptor Activation Studies
Research Overview
CJC-1295 and Ipamorelin represent distinct research compounds studied in cell-based assay formats for their interactions with growth hormone axis signalling pathways. These peptide research tools demonstrate complementary mechanisms of action, with Ipamorelin functioning as a selective ghrelin receptor agonist and CJC-1295 acting as a growth hormone-releasing hormone (GHRH) receptor modulator. Published in vitro research characterises their molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
The combination of these compounds in dual receptor activation studies provides researchers with experimental models for investigating complex neuroendocrine signalling cascades. Cell-based assays utilising both peptides allow examination of synergistic receptor pharmacology effects across multiple signalling pathways simultaneously.
Ipamorelin Receptor Pharmacology and Mechanism of Action
GHSR-1a Receptor Binding Characteristics
Ipamorelin acts via selective GHSR-1a (ghrelin receptor) activation, classified as a class A G-protein-coupled receptor utilising Gq/calcium mobilisation signalling pathways. Competitive radioligand binding assays demonstrate high selectivity for GHSR-1a over related receptor subtypes, with binding affinity (Ki) values typically measured in the nanomolar range in cell membrane preparations.
Functional assays in recombinant cell systems expressing GHSR-1a receptors show dose-dependent activation of phospholipase C (PLC) and subsequent inositol phosphate (IP) accumulation. Calcium mobilisation studies using fluorometric imaging demonstrate rapid intracellular calcium elevation following Ipamorelin treatment in GHSR-1a-expressing cell lines.
Downstream Signalling Pathway Activation
Following GHSR-1a binding, Ipamorelin initiates canonical Gq signalling through PLC-β activation, leading to IP3 and DAG generation. This results in protein kinase C (PKC) activation and calcium-dependent signalling cascade initiation. In pituitary somatotroph cell models, these pathways converge on transcriptional regulation of growth hormone gene expression and peptide hormone secretion mechanisms.
Electrophysiological studies in patch-clamp assays demonstrate Ipamorelin-mediated modulation of voltage-gated calcium channels, contributing to cellular excitability changes in responsive cell types.
CJC-1295 Receptor Pharmacology and GHRH Receptor Interactions
GHRH Receptor Binding and Activation Profile
CJC-1295 functions as a growth hormone-releasing hormone receptor (GHRHR) agonist, targeting class B GPCRs coupled to Gs protein signalling pathways. Radioligand displacement assays reveal competitive binding at GHRHR sites with extended residence time compared to native GHRH peptide sequences.
The modified peptide structure of CJC-1295 incorporates drug affinity complex (DAC) technology, resulting in altered pharmacokinetic properties in cell culture systems. Binding kinetics studies demonstrate prolonged receptor occupancy periods in GHRHR-expressing cell lines.
cAMP-Dependent Signalling Mechanisms
GHRHR activation by CJC-1295 stimulates adenylyl cyclase through Gs protein coupling, resulting in cyclic adenosine monophosphate (cAMP) elevation. Functional assays measuring cAMP accumulation show sustained activation profiles compared to unmodified GHRH peptides in pituitary cell models.
Protein kinase A (PKA) activation downstream of cAMP generation leads to CREB phosphorylation and subsequent transcriptional activation of growth hormone gene expression. Luciferase reporter assays demonstrate dose-dependent activation of cAMP response element (CRE)-driven gene expression following CJC-1295 treatment.
Dual Receptor Activation Studies
Synergistic Pathway Interactions
Combined treatment protocols using both CJC-1295 and Ipamorelin in cell culture systems reveal potential synergistic effects on growth hormone signalling pathways. Dual receptor activation engages both Gs/cAMP and Gq/calcium signalling mechanisms simultaneously, providing convergent stimulation of downstream effector pathways.
Cell viability and proliferation assays in myocyte and fibroblast cell lines demonstrate enhanced responses to combined peptide treatments compared to individual compound applications. These effects appear mediated through complementary activation of growth factor signalling cascades and cellular metabolism pathways.
Enzyme Kinetics and Binding Competition Studies
Competitive binding assays examining receptor selectivity confirm minimal cross-reactivity between CJC-1295 and Ipamorelin at their respective target receptors. Enzyme kinetics analysis of downstream effector activation shows distinct temporal profiles for each compound, with CJC-1295 producing sustained cAMP elevation while Ipamorelin generates rapid calcium transients.
Research Summary
CJC-1295 and Ipamorelin provide complementary research tools for investigating growth hormone axis signalling through distinct GPCR pathways. Ipamorelin's selective GHSR-1a activation and CJC-1295's GHRHR modulation offer researchers dual-pathway experimental models for examining complex neuroendocrine signalling mechanisms. Combined treatment protocols demonstrate synergistic effects on cellular signalling cascades, making this peptide combination valuable for in vitro studies of growth factor pathway interactions and receptor pharmacology characterisation in controlled laboratory environments.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML